Advertisement
Singapore markets open in 6 hours 32 minutes

  • Straits Times Index

    3,306.02
    +6.02 (+0.18%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • Dow

    39,150.33
    +15.53 (+0.04%)
     

  • Nasdaq

    17,689.36
    -32.24 (-0.18%)
     

  • Bitcoin USD

    64,038.66
    -215.48 (-0.34%)
     

  • CMC Crypto 200

    1,320.90
    -39.43 (-2.90%)
     

  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     

  • Gold

    2,334.70
    -34.30 (-1.45%)
     

  • Crude Oil

    80.59
    -0.70 (-0.86%)
     

  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     

  • Nikkei

    38,596.47
    -36.53 (-0.09%)
     

  • Hang Seng

    18,028.52
    -306.78 (-1.67%)
     

  • FTSE Bursa Malaysia

    1,590.37
    -2.32 (-0.15%)
     

  • Jakarta Composite Index

    6,879.98
    +60.66 (+0.89%)
     

  • PSE Index

    6,158.48
    -186.08 (-2.93%)
     

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Business Wire
·1-min read

REDWOOD CITY, Calif. & BOSTON, May 29, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 5-6, 2024 in New York.

Details of the event are as follows:
Date: Wednesday, June 5, 2024
Time: 1:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

ADVERTISEMENT

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529302537/en/

Contacts

Adicet Bio, Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com